YOKNEAM, ISRAEL--(Marketwire - Mar 2, 2012) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, announced today that is has closed its [ previously announced acquisition ] of Ultrashape Ltd. ("Ultrashape"), a leading developer, manufacturer and marketer of innovative non-invasive technologies for fat cell destruction and body sculpting.

The integration of the Ultrashape business will begin immediately and its products, which are approved and commercially available in Europe, Canada, Latin America and Asia, will now be available through Syneron's worldwide network of direct and distributor sales channels.

Louis P. Scafuri, Chief Executive Officer of Syneron Medical, said, "The addition of Ultrashape's unique focused ultrasound technology will provide Syneron immediate entry into the large and attractive global market for fat cell destruction and body sculpting. Ultrashape's technology provides a differentiated, physician and patient friendly, non-invasive treatment for de-bulking and body sculpting of normal to overweight patients. We see tremendous opportunity to leverage our global channel to market capabilities to drive adoption of the Ultrashape system and, combined with our pipeline of new body contouring products, become the market leader in the category. We are very excited to welcome the Ultrashape team to Syneron and look forward to working with them to begin our U.S. clinical trial and continue broadening global exposure for this important technology."

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.